Naruhiko Ikoma1,2, Janice N Cormier1, Barry Feig1, Xianglin L Du2, Jose-Miguel Yamal3, Wayne Hofstetter4, Prajnan Das5, Jaffer A Ajani6, Christina L Roland1, Keith Fournier1, Richard Royal1, Paul Mansfield1, Brian D Badgwell1. 1. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas Health Science Center at Houston, Houston, Texas. 3. Department of Biostatistics, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas. 4. Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: No studies have investigated whether race/ethnicity is associated with the recommended use of preoperative chemotherapy or subsequent outcomes in gastric cancer. To determine whether there is such an association, analyses of patients with gastric cancer in the National Cancer Data Base (NCDB) were performed. METHODS: Patients with clinical T2-4bN0-1M0 gastric adenocarcinoma, as defined by the eighth edition of the American Joint Committee on Cancer staging manual, who underwent gastrectomy from 2006 to 2014 were identified from the NCDB. Multiple logistic regression was conducted to examine factors associated with preoperative chemotherapy use. RESULTS: This study identified 16,945 patients who met the criteria, and 8286 of these patients (49%) underwent preoperative chemotherapy. The use of preoperative chemotherapy remarkably increased over the study period, from 34% in 2006 to 65% in 2014. Preoperative chemotherapy was more commonly used for cardia tumors than noncardia tumors (83% vs 44% in 2014). In a multivariable analysis, races and ethnicities other than non-Hispanic (NH) white race were associated with less frequent use of preoperative chemotherapy in comparison with NH whites after adjustments for social, tumor, and hospital factors. The insurance status and the education level mediated an enhanced effect of racial/ethnic disparities in preoperative chemotherapy use. The use of preoperative chemotherapy and radiation therapy was associated with reduced racial/ethnic disparities in overall survival. CONCLUSIONS: Racial/ethnic disparities in the use of preoperative chemotherapy and in outcomes exist among patients with gastric cancer in the United States. Efforts to improve the access to high-quality cancer care in minority groups may reduce racial disparities in gastric cancer in the United States. Cancer 2018;124:998-1007.
BACKGROUND: No studies have investigated whether race/ethnicity is associated with the recommended use of preoperative chemotherapy or subsequent outcomes in gastric cancer. To determine whether there is such an association, analyses of patients with gastric cancer in the National Cancer Data Base (NCDB) were performed. METHODS:Patients with clinical T2-4bN0-1M0 gastric adenocarcinoma, as defined by the eighth edition of the American Joint Committee on Cancer staging manual, who underwent gastrectomy from 2006 to 2014 were identified from the NCDB. Multiple logistic regression was conducted to examine factors associated with preoperative chemotherapy use. RESULTS: This study identified 16,945 patients who met the criteria, and 8286 of these patients (49%) underwent preoperative chemotherapy. The use of preoperative chemotherapy remarkably increased over the study period, from 34% in 2006 to 65% in 2014. Preoperative chemotherapy was more commonly used for cardia tumors than noncardia tumors (83% vs 44% in 2014). In a multivariable analysis, races and ethnicities other than non-Hispanic (NH) white race were associated with less frequent use of preoperative chemotherapy in comparison with NH whites after adjustments for social, tumor, and hospital factors. The insurance status and the education level mediated an enhanced effect of racial/ethnic disparities in preoperative chemotherapy use. The use of preoperative chemotherapy and radiation therapy was associated with reduced racial/ethnic disparities in overall survival. CONCLUSIONS: Racial/ethnic disparities in the use of preoperative chemotherapy and in outcomes exist among patients with gastric cancer in the United States. Efforts to improve the access to high-quality cancer care in minority groups may reduce racial disparities in gastric cancer in the United States. Cancer 2018;124:998-1007.
Authors: Naruhiko Ikoma; Mariela Blum; Yi-Ju Chiang; Jeannelyn S Estrella; Sinchita Roy-Chowdhuri; Keith Fournier; Paul Mansfield; Jaffer Ajani; Brian D Badgwell Journal: Ann Surg Oncol Date: 2016-10-24 Impact factor: 5.344
Authors: J J Dignam; L Colangelo; W Tian; J Jones; R Smith; D L Wickerham; N Wolmark Journal: J Natl Cancer Inst Date: 1999-11-17 Impact factor: 13.506
Authors: Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar Journal: J Natl Compr Canc Netw Date: 2016-10 Impact factor: 11.908
Authors: James J Dignam; Yunrong Ye; Linda Colangelo; Roy Smith; Eleftherios P Mamounas; H Samuel Wieand; Norman Wolmark Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544
Authors: Trevor Leong; B Mark Smithers; Michael Michael; Val Gebski; Alex Boussioutas; Danielle Miller; John Simes; John Zalcberg; Karin Haustermans; Florian Lordick; Christoph Schuhmacher; Carol Swallow; Gail Darling; Rebecca Wong Journal: BMC Cancer Date: 2015-07-21 Impact factor: 4.430
Authors: Vignesh Raman; Oliver K Jawitz; Soraya L Voigt; Kristen E Rhodin; Anthony W Kim; Betty C Tong; Thomas A D'Amico; David H Harpole Journal: Ann Thorac Surg Date: 2020-07-03 Impact factor: 4.330
Authors: Sarah R Kaslow; Zhongyang Ma; Leena Hani; Katherine Prendergast; Gerardo Vitiello; Ann Y Lee; Russell S Berman; Judith D Goldberg; Camilo Correa-Gallego Journal: J Surg Oncol Date: 2022-04-26 Impact factor: 2.885
Authors: Naruhiko Ikoma; Jeannelyn S Estrella; Mariela Blum Murphy; Prajnan Das; Bruce D Minsky; Paul Mansfield; Jaffer A Ajani; Brian D Badgwell Journal: J Gastrointest Surg Date: 2020-06-15 Impact factor: 3.452
Authors: Casey J Allen; Alisa N Blumenthaler; Grace L Smith; Prajnan Das; Bruce D Minsky; Mariela Blum; Jaffer Ajani; Paul F Mansfield; Naruhiko Ikoma; Brian D Badgwell Journal: Ann Surg Oncol Date: 2020-07-21 Impact factor: 5.344
Authors: Casey J Allen; David T Pointer; Alisa N Blumenthaler; Rutika J Mehta; Sarah E Hoffe; Bruce D Minsky; Grace L Smith; Mariela Blum; Paul F Mansfield; Naruhiko Ikoma; Prajnan Das; Jaffer Ajani; Sean P Dineen; Jason B Fleming; Brian D Badgwell; Jose M Pimiento Journal: Ann Surg Date: 2021-10-01 Impact factor: 13.787
Authors: Vignesh Raman; Oliver K Jawitz; Norma E Farrow; Soraya L Voigt; Kristen E Rhodin; Chi-Fu J Yang; Megan C Turner; Thomas A D'Amico; David H Harpole; Betty C Tong Journal: Ann Surg Date: 2022-03-01 Impact factor: 13.787